Stoke Therapeutics, Inc. · NASDAQ:STOK
Allan Jonathan sold 2,861 Stoke Therapeutics, Inc. shares (Form 4)
Traded Aug 14 to Aug 18, 2026 · Filed Aug 18, 2026
From Aug 14 to Aug 18, 2026, Allan Jonathan (GENERAL COUNSEL & CORP SEC) sold 2,861 Stoke Therapeutics, Inc. shares at an average US$32.03 for US$91,647, leaving 21,225 shares. Filed Aug 18, 2026 (Form 4).
- Sold
- 2,861 shares
- Price
- US$32.03 average (US$32.01 to US$32.47)
- Value
- US$91,647
- Holding after
- 21,225 shares
- Trading plan
- No
- Role
- GENERAL COUNSEL & CORP SEC
The filing in full
| Date | Security | Transaction | Shares | Price | Holding after | Ownership |
|---|---|---|---|---|---|---|
| Aug 14, 2026 | Common Stock | Option exercise | 6,000 | 24,086 | Direct | |
| Aug 18, 2026 | Common Stock | Sale | 2,716 | US$32.01 | 21,370 | Direct |
| Aug 18, 2026 | Common Stock | Sale | 145 | US$32.47 | 21,225 | Direct |
Source
Related
- Stoke Therapeutics, Inc.
- Allan Jonathan
- Stoke Therapeutics, Inc. shareholders
- Form 4 · Allan Jonathan · Oct 2, 2026
- Form 4 · Allan Jonathan · Jun 18, 2026
- Form 4 · Ticho Barry · Oct 2, 2026
- Schedule 13G · Biotechnology Value Fund L P · Sep 30, 2026
- Form 4 · Ticho Barry · Sep 3, 2026
- Form 4 · Ticho Barry · Aug 18, 2026
- Form 4 · Kaye Edward M. MD · Aug 18, 2026